The interest and demand for regenerative medicine for various conditions and injuries have increased exponentially over the last decade. From January 1, 1990 to December 31, 2012, google searches for regenerative medicine totaled 21,600,000. With increased publicity about stem cells and advancements in cell and gene therapies, biomaterials and tissue engineering, google searches increased nearly ten-fold to 212,000,000 from 1/1/13 to 2/27/23.

• PRP Trends and the Impacts to 2023 and Beyond
  
  • Headwinds in 2023
  • Trends in PRP Clinical Trials
  • Anticipated 2023 US PRP Market Share Standings
• Adipose Trends and the Impacts to 2023 and Beyond
  • Adipose tissue therapy gaining interest in the field of sports medicine
  • Patient demand for minimally-invasive solutions
  • Adipose-derived cell therapies for OA and Degenerative Disc Disease
    

So is regenerative medicine the way of the future? Time will tell, however, SmartTRAK feels that demand and interest by multiple stakeholders, along with recent trends, medical and legal advancements and investments is tipping the scale to ...

To download and read the complete "A Glimpse into 2023: Regen Med Trends" article by Freddy Buntoum, SmartTRAK's Senior Analyst, Orthobiologics and Regenerative Medicine, just click the button below.

SmartTRAK reviews recent trends in hernia matrices and their potential impact on the US Hernia Matrices Market, which is projected to reach $1.06B in 2023 according to SmartTRAK.

Incisional hernia procedures reached a peak in the mid-2000s, with a gradual decline as surgeons performed fewer abdominal procedures and researchers investigated new techniques for closure. While improved stitching for closure has had mixed results, surgeons are trying other new approaches to reduce incisional hernias such as MSI’s DuraMesh* and Deep Blue Medical’s T-line mesh* which are being used prophylactically.

In this Market Outlook article, we cover in detail:

• Synthetic Matrices Poised for Slow Down
• Alternatives to Synthetic Matrices Gaining Favor
  • Xenograft Matrices
  • Resorbable Meshes
  • Reinforced Xenograft Matrices
• Expert Analysis and Conclusions

Market Dynamics, Industry Moves and Technology Advancements 

In 2022, the Orthobiologics Market encountered both ups and downs. Though companies are still reporting year-end results, SmartTRAK feels the Orthobiologics Market finished on a high note. The 2022 challenges, such as staffing shortages at healthcare facilities, supply chain constraints and inflation, may cause headwind in 2023, stifling some growth.

Nevertheless, SmartTRAK anticipates the potential downsides will be offset by elective procedures returning to pre-COVID levels, along with progressive, transitional initiatives by select market players that have the potential to reshape certain orthobiologics segment landscapes.

Among the many topics covered in this Market Outlook article are:

• Reshaping the Competitive Landscape
• Shifts in the US Bone Replacement Market
• Advancements in Osteobiologics
• Shifts in the US Sports Medicine Market

Do you love keeping up with the latest trends in the Spine and OrthoBiologics/Regen medicine markets? Are you a closet investigative reporter who loves researching and analyzing what’s going on in the market? Are you looking for a position that leverages your industry knowledge, expertise and connections in new ways? If you are a current or former marketing, market research or business development professional who has worked with one of the major orthopedic/spine companies and looking for a career change, we would love to talk with you.

We are looking to strengthen our SmartTRAK Spine and OrthoBiologics/Regen modules with the addition of a qualified person with industry specific experience. All SmartTRAK analysts are former marketing, business development or R&D professionals with one of the major orthopedic/spine suppliers and, in fact, most have come to us via recommendations from our subscribers, as well as those in the industry. We believe that having a person of this caliber with relevant experience and deep insight on the market is a tremendous value-add we can offer SmartTRAK subscribers.

We are looking for someone with Spine and OrthoBiologics/Regen industry experience who is interested in working full-time. Click the button below to learn more and apply.

Highlighting the latest research, technology developments and innovations taking place in orthobiologics and regenerative medicine at ICRS 2022

This year the International Cartilage Regenerative & Joint Preservation Society (ICRS) hosted its 16th World Congress in Berlin, Germany, and SmartTRAK covered it. This was the Society’s first in-person meeting since October 2019, and without a doubt, a very exciting moment for ICRS, its members and all who attended the event. For four days, industry stakeholders from around the world converged in Berlin to learn and hear about the latest research, technology developments and innovations taking place in orthobiologics and regenerative medicine. In this article, SmartTRAK gives a recap of some of the main topics presented during the meeting.

Among the many fascinating topics covered in the complete article, which can be downloaded here, are:

• The Role of Extracellular Vesicles 
• Use of Minced Cartilage
• Autologous, Matrix-induced Chondrogenesis 
• Feasibility of Gene Therapy
• Other Therapies of Tomorrow

Observations and analysis from the 37th Annual North American Spine Society (NASS) Meeting held October 12-14 in Chicago, IL. 

SmartTRAK highlights the top news and themes at NASS 2022 affecting the markets for OrthoBio and Regenerative Medicine, including the Orthofix/SeaSpine  merger, the ongoing controversy surrounding BMP-2, new product launches, company growth strategies and the latest research and innovation in intradiscal therapies.

Among the many topics covered in detail in this article are:

• A Spine Merger That Will Significantly Impact The Orthobiologics Landscape
• BMP-2 Safety Profile Remains an Open Issue
• Incremental Product Improvement Across OrthoBio Categories
• Spine Strategic Portfolio Strategies
• Intradiscal Treatments Take Center Stage

Undoubtedly, the proposed business combination of Orthofix and SeaSpine announced immediately prior to NASS was the most impactful news emanating from the meeting. On a proforma basis, the combined company is expected to generate approximately ...

To download and read the complete "OrthoBio-Focused Themes Emerging from NASS 2022" article by James Petricek,  SmartTRAK's GM, OrthoBio and Regenerative Medicine, just click the button below.

Mr J. David Owens, President & CEO of BiologicsMD, and Chief Scientific Officer, Dr. Robyn Goforth, discuss the Company’s highly-targeted therapies, a series of recombinant fusion proteins designed to treat hair loss and severe bone disorders, in an interview with SmartTRAK.

In an interview with SmartTRAK, BiologicsMD President & CEO J. David Owens and CSO Dr. Robyn Goforth discuss BiologicsMD’s innovative highly-targeted treatments for severe bone disorders and hair loss diseases.

To find out more about this early-stage company, the science behind highly-targeted therapies, and two of its lead compounds, click on the following video to listen to the full interview (29:10 min). A link to download a complete transcript of the interview is also provided below.

Q122 started slow but ended on a bright note as COVID-19 concerns faded and surgical volumes approached pre-pandemic levels.

Virtually all orthopedic/spine companies experienced the same pattern with elective procedures during the quarter. In general, elective procedure case counts were pressured in January through the beginning of February as a surge in COVID-19 cases impacted patients and contributed to staffing shortages at healthcare facilities. However, by the end of the quarter elective procedures approached or returned to pre-COVID levels.

Among the many topics covered in detail in our comprehensive Q122 OrthoBio Market Recap* are:

For Q122, US Joint Fluid Replacement market players continued on a running growth, which did not seem too disrupted by the COVID Omicron variant. Furthermore, some players shared that despite physicians’ offices not yet running at 100% levels, company sales representatives were able to hold face-to-face visits and secure new orders.